Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co. (NYSE:LLY) has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
Eli Lilly and Co.紐約證券交易所代碼：LLY）已任命盧卡斯·蒙塔斯爲執行副總裁兼首席財務官，立即生效。
What Happened: Montarce, who joined Lilly in 2001, has held numerous finance leadership positions. His roles included group vice president, corporate controller, and CFO of Lilly Research Laboratories; vice president, finance and CFO of Lilly International; and vice president, finance, and global CFO of Elanco Health.
發生了什麼：蒙塔斯於2001年加入禮來公司，曾擔任過許多財務領導職務。他的職位包括禮來研究實驗室的集團副總裁、公司財務總監兼首席財務官；禮來國際的財務副總裁兼首席財務官；以及Elanco Health的財務副總裁兼全球首席財務官。
Most recently, Montarce served as Lilly's president and general manager for the Spain, Portugal, and Greece hub. He holds a bachelor's degree in business accounting from Catholic University (Argentina) and a master's degree in business administration from the Center for Macroeconomic Studies of Argentina.
最近，蒙塔斯擔任禮來公司總裁兼西班牙、葡萄牙和希臘樞紐總經理。他擁有天主教大學（阿根廷）的商業會計學士學位和阿根廷宏觀經濟研究中心的工商管理碩士學位。
David Ricks, chair and CEO stated, "We are excited to announce Lucas as Lilly's next CFO, following a competitive search across health care, tech, and general industries."
董事長兼首席執行官大衛·裏克斯表示：「在對醫療保健、科技和一般行業進行了競爭性搜尋之後，我們很高興地宣佈盧卡斯爲禮來公司的下一任首席財務官。」
Montarce expressed his commitment to building on Lilly's strong financial foundation and driving continued success. "I am honored to step into this role during such a significant time in our company's history," he said.
蒙塔斯表示致力於在禮來公司強大的財務基礎上再接再厲，推動持續取得成功。他說：「我很榮幸能在我們公司歷史上如此重要的時刻擔任這個職務。」
Why It Matters: The appointment of Montarce as CFO comes at a pivotal time for Eli Lilly. The company has been in the spotlight for its advancements in the weight loss and GLP-1 space. Roundhill Investments CEO Dave Mazza recently likened Eli Lilly to NVIDIA Corp (NASDAQ:NVDA) in terms of market leadership and growth potential.
爲何重要：任命蒙塔斯爲首席財務官正值禮來公司的關鍵時刻。該公司因其在減肥和 GLP-1 領域的進步而備受關注。就市場領導地位和增長潛力而言，朗德希爾投資首席執行官戴夫·馬紮最近將禮來公司比作英偉達公司（納斯達克股票代碼：NVDA）。
Additionally, Eli Lilly's Alzheimer's drug, donanemab, is facing potential rejection by the U.K.'s National Health Service (NHS) due to cost and safety concerns, following a similar decision on Biogen Inc's (NASDAQ:BIIB) Leqembi. This has added pressure on the company to navigate regulatory challenges effectively.
此外，禮來公司的阿爾茨海默氏症藥物donanemab可能面臨英國的拒絕。”s 國家衛生服務局（NHS）出於成本和安全考慮，此前對百健公司（納斯達克股票代碼：BIIB）的Leqembi做出了類似的決定。這增加了該公司有效應對監管挑戰的壓力。
Montarce's appointment also follows the resignation of former CFO Anat Ashkenazi, who left to pursue a new career. Gordon Brooks has been serving as interim CFO since Jul. 15.
蒙塔斯的任命也是在前首席財務官阿納特·阿什肯納齊辭職之後被任命的，他離職從事新的職業生涯。戈登·布魯克斯自7月15日起擔任臨時首席財務官。
Moreover, Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. This move is part of a broader strategy to maintain its market position amid ongoing FDA debates about drug shortages.
此外，禮來公司正在加緊努力，打擊其流行的抑制食慾的藥物Mounjaro和Zepbound的仿製版本。在美國食品藥品管理局關於藥品短缺的爭論仍在進行中，此舉是維持其市場地位的更廣泛戰略的一部分。
Price Action: Eli Lilly and Co closed at $908.27 on Monday, gaining 0.62% for the day. In after-hours trading, the stock dipped 0.027%. Year to date, Eli Lilly's stock has surged 53.37%, according to data from Benzing Pro.
價格走勢：禮來公司週一收於908.27美元，當天上漲0.62％。在盤後交易中，該股下跌了0.027％。根據Benzing Pro的數據，今年迄今爲止，禮來公司的股票已飆升了53.37％。
- Job Slowdown? Headhunters Are On A Roll, Revenue For Executive Searches Is Up
- 工作放緩？獵頭大放異彩，獵頭收入上升
Image Via Shutterstock
圖片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
這個故事是使用 Benzinga Neuro 創作的，由 Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。